I do not wish to speak for Mr Paterson, Little Fat Lamb, although I will put my interpretation on the "30-40%" figure.... my interpretation is that this is the figure Mr Paterson believes could be captured in the short-medium term.
Long term I believe that he believes it would be much higher. I have heard him imply and say as much in presentations and interview and it makes sense. The DurAVR wipes the floor with every other TAVR on the market..... there is NO reason, aside from familiarity, that doctors would use a competitors TAVR over ours. Zero. None.
Our advisory board is comprised of TAVR superstars. The best of the best. These are the people who influence and shape professional opinion and they are all strongly advocating for the benefits that The DurAVR will give both the patients (performance, durability) and the doctors (ease and precision of placement, commisural alignment.)
We are a big and juicy target for any major med-tech company currently IN the TAVR market or any major med-tech company wanting to get INTO the TAVR market.
My personal hope is that we go it alone although my feeling is that we will be bought out.
AVR Price at posting:
$25.50 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)